+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Etiology, pathophysiology, and treatment of left ventricular hypertrophy: focus on severe hypertension



Etiology, pathophysiology, and treatment of left ventricular hypertrophy: focus on severe hypertension



Journal of Cardiovascular Pharmacology 21 Suppl 2: S55-S62



Left ventricular hypertrophy (LVH), a common finding in hypertensive patients, has emerged as one of the most potent risk factors for future cardiovascular mortality in patients with hypertension. LVH is associated with multiple physiologic abnormalities, which may account for the increased risk. These include coronary perfusion abnormalities such as reduced coronary flow reserve, altered coronary flow autoregulation, subendocardial hypoperfusion, and abnormal left ventricular (LV) diastolic function. Although abnormalities of LV diastolic function are more common in LVH, they may occur early in the course of the disease. There may be a threshold of average awake ambulatory blood pressure (BP), 130/85 mm Hg, below which neither diastolic abnormalities nor LVH is detected. The reasons for reduced reserve coronary flow reserve are complex and include structural and functional abnormalities of myocardial blood vessels such as reduced capillary density, reduced luminal diameter of intramyocardial small arteries, and increased vascular tone, possibly as a result of factors such as abnormal endothelium-dependent relaxation. Preliminary data suggest that regression of LVH is associated with improved survival. Severe hypertensive patients would be expected to achieve the greatest benefit, because, if left untreated, this group has nearly 20% mortality within 2 years. To evaluate the effect of nifedipine gastrointestinal therapeutic system (GITS) on LV mass, 16 patients with initial diastolic BP > 120 mm Hg were treated for 1 year with either monotherapy or in combination with a thiazide diuretic. Because it has not been unequivocally shown that changes in LV mass have physiologic benefit, associated alterations in LV systolic function, LV filling, plasma renin activity, atrial natriuretic peptide, and catecholamines were also evaluated.

(PDF emailed within 1 workday: $29.90)

Accession: 031304886

Download citation: RISBibTeXText

PMID: 7692152


Related references

Etiology, Pathophysiology, and Treatment of Left Ventricular Hypertrophy. Journal of Cardiovascular Pharmacology 21: S55-S62, 1993

Left ventricular hypertrophy and its regression: Pathophysiology and therapeutic approach. Focus on treatment by antihypertensive agents. American Journal of Hypertension 11(11 PART 1): 1394-1404, 1998

Left ventricular hypertrophy in hypertension: etiology, treatment, and controversies. Mount Sinai Journal of Medicine, New York 65(2): 97-103, 1998

Left Ventricular Hypertrophy in Hypertension. Part III. Reversibility of Left Ventricular Hypertrophy During Treatment With Antihypertensive Drugs. Kardiologiia 44(4): 89-94, 2004

Pathophysiology of left ventricular hypertrophy in arterial hypertension. Praxis 86(7): 234-237, 1997

Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 97(19): 1907-1911, 1998

Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. Journal of Hypertension 20(8): 1527-1533, 2002

Supranormal left ventricular performance with severe left ventricular hypertrophy in essential hypertension. Journal of the American College of Cardiology 7(2 SUPPL A): 186A, 1986

Importance of abnormalities in coronary flow reserve to the pathophysiology of left ventricular hypertrophy secondary to hypertension. Clinical Cardiology 12(12 Suppl 4): Iv34-Iv35, 1989

Left ventricular hypertrophy and its regression: the prothrombic state in hypertension may be involved in its pathophysiology and altered by therapy. American Journal of Hypertension 12(10 Pt 1): 1048-1049, 1999

Echocardiography in clinical pharmacology: developing new concepts on the pathophysiology of left ventricular hypertrophy in arterial hypertension. International Journal of Clinical Pharmacology Research 3(3): 157-161, 1983

The effect of long-term treatment by the angiotensin I-converting enzyme inhibitor enalapril on renal function and left ventricular hypertrophy in severe essential hypertension. Cor et Vasa 32(5): 353-362, 1990

Latent impairment of left ventricular filling in hypertension without left ventricular hypertrophy and improvement by dipyridamole treatment: pulsed Doppler echocardiography study. Journal of Cardiology 25(4): 171-179, 1995

Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment in patients with electrocardiographic left ventricular hypertrophy (LIFE). European Heart Journal 34(Suppl 1): P3232-P3232, 2013

Assessment of left ventricular systolic and diastolic function in physiologic hypertrophy in athletes and left ventricular hypertrophy in hypertension patients using Doppler tissue imaging. Zhongguo Chaosheng Yixue Zazhi 20(11): 820-824, 2004